An immunogenic dose of innate immune adjuvants, which have previously shown to increase immune infiltration without ablating the tumor ADU-S10035 or Poly I:C36, did not generate a detectable OVA-specific T cell population as determined by SIINFEKL tetramer staining (Fig. 1C–D).These data suggest that triggering of the TLR3 or the STING/cGAS pathways does not induce sufficient tumor cell lysis to prime an OT-1 immune response even though in this system the OVA antigen is a fully foreign, non-tolerized TAA. The gene discussed is TLR3; the disease is neoplasm.